NCT01655511View on ClinicalTrials.gov

Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
TTR Cardiomyopathy
Interventions
DRUG

Tafamidis

240 mg, solution, single dose

DRUG

Tafamidis

480 mg, solution, single dose

DRUG

Tafamidis

TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01655511 - Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers | Biotech Hunter | Biotech Hunter